12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Seres Therapeutics (NASDAQ:MCRB) stock moved upwards by 34.0% to $0.82 during Monday’s regular session. The company’s market…
Curis To Present Updated Data From TakeAim Leukemia Study At The ASCO And EHA Conferences
Data update expands AML dataset from 5 to 30 patientsLEXINGTON, Mass., May 14, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally
Top 3 Health Care Stocks That May Collapse In Q2
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
12 Health Care Stocks Moving In Thursday’s Intraday Session
Gainers Candel Therapeutics (NASDAQ:CADL) shares moved upwards by 64.3% to $2.76 during Thursday’s regular session. The market value…
CyberArk Software To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell
• Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.
Curis’s Earnings: A Preview
Curis (NASDAQ:CRIS) is set to give its latest quarterly earnings report on Thursday, 2024-02-08. Here’s what investors need…
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes.
BlackBerry shares tumbled 17.2% to $2.9387 on Wednesday.
12 Health Care Stocks Moving In Wednesday’s Intraday Session
Gainers Kura Oncology (NASDAQ:KURA) stock rose 48.1% to $19.87 during Wednesday’s regular session. The market value of their…
Curis Announces Initial Combination Study Data From Its TakeAim Lymphoma Study
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combination study data from its TakeAim